Streetbeat News

Products Services

SLDB

Solid Biosciences has entered into a non-exclusive licensing agreement for the use of its proprietary, muscle-targeted AAV-SLB101 capsid.

Portfolio Pulse from Charles Gross

March 13, 2024 | 11:51 am

IONS

Ionis Pharmaceuticals' shares surged following the announcement of positive results from its Phase 2 study of ION224.

Portfolio Pulse from Benzinga Newsdesk

March 13, 2024 | 11:46 am

MU

NVDA

QOWZ

SSNLF

TRFK

Samsung Electronics is adopting a new chip-making technology to compete in the AI chip market, aiming to improve its position against SK Hynix and Micron Technology. SK Hynix leads with over 80% market share in HBM3 chips, supplied mainly to Nvidia, which has seen a 91% stock increase year-to-date due to AI demand. Samsung's shift from NCF to MUF technology is expected to enhance its HBM production yields, which currently lag behind SK Hynix's. Investors can gain exposure to Nvidia through ETFs like QOWZ and TRFK.

Portfolio Pulse from Anusuya Lahiri

March 13, 2024 | 11:44 am

ARCO

Arcos Dorados announced plans to open 80 to 90 new restaurants in 2024, with approximately 90% being free-standing units. The company anticipates total capital expenditures for 2024 to be between $300M and $350M.

Portfolio Pulse from Benzinga Newsdesk

March 13, 2024 | 11:36 am

AGFY

Agrify Corporation (AGFY) has entered into a turnkey extraction equipment deal with Justice Cannabis Co., marking its expansion into the New Jersey market. This partnership signifies Agrify's strategic move to enhance its presence in the rapidly growing cannabis industry by providing state-of-the-art extraction equipment to a leading multi-state operator.

Portfolio Pulse from Benzinga Newsdesk

March 13, 2024 | 11:34 am

DV

DoubleVerify Holdings, Inc. (NYSE:DV) has expanded its collaboration with NBCUniversal to offer program-level measurement solutions for OTT devices, including Connected TV (CTV). This partnership aims to provide NBCUniversal advertisers with tools to assess brand safety, suitability, and content performance at the program level. The company, which has seen a 34% increase in its stock over the last year, expects Q1 revenue of $136 million to $140 million and full-year 2024 revenue of $688 million to $704 million, marking a 22% increase at the midpoint. Macquarie analyst Tim Nollen upgraded DoubleVerify from Neutral to Outperform with a $40 price target.

Portfolio Pulse from Nabaparna Bhattacharya

March 13, 2024 | 11:33 am

AGFY

Agrify Corporation (NASDAQ:AGFY), a leader in cultivation and extraction solutions for the cannabis industry, has announced a deal with Justice Cannabis Co. to provide a comprehensive hydrocarbon extraction and lab equipment package as Justice Cannabis expands into the New Jersey market. This package includes a variety of extraction and lab equipment, as well as a UL-Compliant C1D1 Explosion Proof Room, designed for safe and easy installation.

Portfolio Pulse from Benzinga Newsdesk

March 13, 2024 | 11:32 am

PRTC

PureTech Health announced that the FDA has granted Orphan Drug Designation to LYT-200 for the treatment of Acute Myeloid Leukemia. This designation could potentially accelerate LYT-200's development and approval process, offering a new treatment option for patients with this condition.

Portfolio Pulse from Benzinga Newsdesk

March 13, 2024 | 11:24 am

BCDA

BioCardia has entered into a long-term partnership with StemCardia to advance the latter's investigational pluripotent stem cell product candidate for treating heart failure. BioCardia will be the exclusive biotherapeutic delivery partner throughout the FDA approval process for an investigational new drug application (IND) and the expected Phase I/II clinical trials.

Portfolio Pulse from Benzinga Newsdesk

March 13, 2024 | 11:14 am

PCRX

Pacira Biosciences announced that the FDA has granted Regenerative Medicine Advanced Therapy (RMAT) designation to its gene therapy product, PCRX-201 (Enekinragene Inzadenovec), for the treatment of knee osteoarthritis. This designation could expedite the development and review process for PCRX-201, potentially bringing it to market faster.

Portfolio Pulse from Benzinga Newsdesk

March 13, 2024 | 11:12 am